OncoQR ML

OncoQR ML is an Austrian pre-clinical biotech startup focused on next-generation cancer immunotherapies. The company's vision is to defeat cancer by activating all four of the immune system's natural tumor-killing mechanisms in parallel through its Active Checkpoint Control Immunotherapy (ACCI) approach. Its foundational S-TIR™ technology platform, in-licensed from S-TARget therapeutics GmbH, serves as the basis for therapeutic cancer vaccines and is offered for out-licensing on a target-by-target basis. The company has achieved in vivo proof-of-concept for two lead candidates and is led by senior pharma professionals with extensive R&D and management experience.

S-TIR™ platform: an Adjustable Cancer Immunotherapy (ACI) platform enabling Active Checkpoint Control Immunotherapy (ACCI) designed to activate all four natural tumor-killing mechanisms (CTLs, ADCC, CDC, Apoptosis) in a tumor-specific manner.

OncoQR ML competes in the broad and crowded cancer immunotherapy space, which includes giants like Merck, Bristol-Myers Squibb, and Roche, as well as numerous biotechs developing next-gen vaccines, cell therapies, and bispecific antibodies. Its key differentiator is the claim of simultaneously activating four distinct immune killing mechanisms via its proprietary S-TIR™ platform.